中国药业
中國藥業
중국약업
China Pharmaceuticals
2015年
17期
37-38
,共2页
巴氯芬%儿童%难治性胃食管反流性咳嗽%临床疗效%安全性
巴氯芬%兒童%難治性胃食管反流性咳嗽%臨床療效%安全性
파록분%인동%난치성위식관반류성해수%림상료효%안전성
baclofen%children%refractory gastroesoPhageal reflux induced cough%clinical effcacy%safety
目的：观察巴氯芬用于儿童难治性胃食管反流性咳嗽治疗的临床疗效及安全性。方法选择2014年收治的难治性胃食管反流性咳嗽患儿80例，随机分为观察组与对照组，各40例。两组均指导调节生活方式，对照组予多潘立酮片(每次0.3 mg/kg，3次/日)，奥美拉唑镁肠溶片（每次20 mg，1次/日）。观察组在对照组的基础上加用巴氯芬片（每次0.25 mg/kg，4次/日）。两组患儿疗程均为8周。观察并记录患儿治疗期间咳嗽、反酸、胸骨后灼热感以及嗳气等临床症状的变化，并对治疗前后临床症状的严重程度、症状发生频率进行评分。观察患者治疗前后。记录治疗前后患者血常规、肝肾功能及不良反应。结果治疗后，观察组临床疗效总有效率为92.50％，明显高于对照组的67.50％（ P ＜0.05）。与治疗前比较，两组患儿治疗后各项症状积分及症状总积分均有减少（ P＜0.05），且观察组减少程度更加明显（ P＜0.05）。观察组的不良反应发生率为22.50％，明显高于对照组的7.50％（ P＜0.05），均能耐受，不影响后续治疗。两组患儿用药前后血常规、肝肾功能均未见明显变化。结论巴氯芬可有效治疗儿童难治性胃食管反流性咳嗽，虽然存在一定程度的嗜睡、乏力等不良反应，但能明显改善患儿的临床症状，可对抑酸治疗不能完全缓解症状的患儿进行辅助治疗。
目的：觀察巴氯芬用于兒童難治性胃食管反流性咳嗽治療的臨床療效及安全性。方法選擇2014年收治的難治性胃食管反流性咳嗽患兒80例，隨機分為觀察組與對照組，各40例。兩組均指導調節生活方式，對照組予多潘立酮片(每次0.3 mg/kg，3次/日)，奧美拉唑鎂腸溶片（每次20 mg，1次/日）。觀察組在對照組的基礎上加用巴氯芬片（每次0.25 mg/kg，4次/日）。兩組患兒療程均為8週。觀察併記錄患兒治療期間咳嗽、反痠、胸骨後灼熱感以及噯氣等臨床癥狀的變化，併對治療前後臨床癥狀的嚴重程度、癥狀髮生頻率進行評分。觀察患者治療前後。記錄治療前後患者血常規、肝腎功能及不良反應。結果治療後，觀察組臨床療效總有效率為92.50％，明顯高于對照組的67.50％（ P ＜0.05）。與治療前比較，兩組患兒治療後各項癥狀積分及癥狀總積分均有減少（ P＜0.05），且觀察組減少程度更加明顯（ P＜0.05）。觀察組的不良反應髮生率為22.50％，明顯高于對照組的7.50％（ P＜0.05），均能耐受，不影響後續治療。兩組患兒用藥前後血常規、肝腎功能均未見明顯變化。結論巴氯芬可有效治療兒童難治性胃食管反流性咳嗽，雖然存在一定程度的嗜睡、乏力等不良反應，但能明顯改善患兒的臨床癥狀，可對抑痠治療不能完全緩解癥狀的患兒進行輔助治療。
목적：관찰파록분용우인동난치성위식관반류성해수치료적림상료효급안전성。방법선택2014년수치적난치성위식관반류성해수환인80례，수궤분위관찰조여대조조，각40례。량조균지도조절생활방식，대조조여다반립동편(매차0.3 mg/kg，3차/일)，오미랍서미장용편（매차20 mg，1차/일）。관찰조재대조조적기출상가용파록분편（매차0.25 mg/kg，4차/일）。량조환인료정균위8주。관찰병기록환인치료기간해수、반산、흉골후작열감이급애기등림상증상적변화，병대치료전후림상증상적엄중정도、증상발생빈솔진행평분。관찰환자치료전후。기록치료전후환자혈상규、간신공능급불량반응。결과치료후，관찰조림상료효총유효솔위92.50％，명현고우대조조적67.50％（ P ＜0.05）。여치료전비교，량조환인치료후각항증상적분급증상총적분균유감소（ P＜0.05），차관찰조감소정도경가명현（ P＜0.05）。관찰조적불량반응발생솔위22.50％，명현고우대조조적7.50％（ P＜0.05），균능내수，불영향후속치료。량조환인용약전후혈상규、간신공능균미견명현변화。결론파록분가유효치료인동난치성위식관반류성해수，수연존재일정정도적기수、핍력등불량반응，단능명현개선환인적림상증상，가대억산치료불능완전완해증상적환인진행보조치료。
Objective To observe the clinical effect and safety of baclofen for treating children with refractory gastroesoPhageal reflux in-duced cough. Methods 80 cases of refractory gastroesoPhageal reflux induced cough in the hosPital were randomly selected and divided into the observation grouP and the control grouP,40 cases in each grouP. Both grouPs were guided to adjust the way of life. The control grouP was treated with DomPeridone Tablets [ 0. 3 mg/ ( kg · time ) ,3 times/d ] ,OmePrazole Magnesium Enteric-Coated Tablets (20 mg/time,1 time/d). The observation grouP received baclofen tablets[0. 25 mg/ (kg·time),4 times/d] on the basis of the control grouP. The two grouPs were treated for 8 weeks. Observe and record the changes of cough,acid regurgitation,retrosternal burning sen-sation,and belching and other clinical symPtoms in the Patients during the treatment,and evaluate the scores of the clinical symPtom severity and symPtom frequency before treatment and after treatment. Observe the Patients before and after treatment. The changes of blood routine,liver and kidney function and adverse reaction were recorded before and after treatment. Results After treatment,the clin-ical efficacy of the observation grouP was 92. 50%,which was significantly higher than 67. 50% of the control grouP,the difference was statistically significant ( P < 0. 05 ) . ComPared with before treatment,the symPtom score and total score of symPtoms in the two grouPs were decreased,the difference is statistically significant ( P < 0. 05 ) and the observation grouP decreased more significantly,with signifi-cant difference ( P < 0. 05 ) . The incidence rate of adverse reactions in the observation grouP was 22. 50% which was obviously higher than 7. 50% in the control grouP ( P < 0. 05 ) ,and the adverse reactions were tolerable. The two grouPs before and after medication in children,the changes of blood routine,liver and kidney function changes were not found in the two grouPs. Conclusion Baclofen can be effective in the treatment of children with refractory gastroesoPhageal reflux cough,although there is a certain degree of drowsiness, fatigue,and other adverse reactions,but can really imProve the children's clinical symPtoms,and can be an additional treatment when the anti acid treatment can not achireve comPlete remission of symPtoms in children.
